• Rapports/études/travaux (documents) (0)
  • Rapports/études/travaux (collections) (0)
  • Législation et Réglementation (0)
  • Statistiques, Chiffres et données (0)
  • Organismes de recherche (0)
  • Organisations gouv. et internationales (0)
  • ONG, Associations, Entreprises (0)
  • Outils de recherche de l'information (0)
  • Tous les types (0)


2012-Beyond borders. Global biotechnology report (27th edition)$FILE/Beyond_borders_2012.pdf

Rapports/études/travaux (collections)

langue Anglaise

Comme tous les ans, le groupe Ernst & Young publie un rapport sur les biotechnologies dans le monde. Ce rapport est le 27ème de cette série.

Résumé de l'éditeur :

Our analysis of trends across the leading centers of biotech activity reveals both signs of hope and causes for concern. The financial performance of publicly traded companies is more robust than at any time since the onset of the global financial crisis, with the industry returning to double-digit revenue growth. Companies that had made drastic cuts in R&D spending in the aftermath of the crisis are now making substantial increases in their pipeline development efforts. But even as things are heading back to normal on the financial performance front, the financing situation remains mired in the "new normal" we have been describing for the last few years. While the biotech industry raised more capital in 2011 than at any time since the genomics bubble of 2000, this increase was driven entirely by large debt financings by the industry's commercial leaders. The money flowing to the vast majority of smaller firms, including pre-commercial, R&D-phase companies — a measure we refer to as "innovation capital" — has remained flat for the last several years. As such, the question we have posed for the last two years is more relevant than ever: how can biotech innovation be sustained during a time of serious resource constraints?

Ernst & Young, 92 p., 2012

01 février 2013


Retour vers la page précédente